跳转至内容
Merck
CN

Y0001400

氨己烯酸

European Pharmacopoeia (EP) Reference Standard

别名:

(±)-Vigabatrin, (R,S)-4-氨基-5-己烯酸, (±)-γ-乙烯基-GABA, (±)-4-氨基己酸

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C6H11NO2
化学文摘社编号:
分子量:
129.16
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

SMILES string

NC(CCC(O)=O)C=C

InChI key

PJDFLNIOAUIZSL-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

vigabatrin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... ABAT(18)

正在寻找类似产品? 访问 产品对比指南

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Vigabatrin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

不可逆的 GABA 转氨酶抑制剂。增加神经末梢的胞内 GABA 浓度;具有抗癫痫活性。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

STOT RE 1

target_organs

Eyes,Central nervous system

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

M K Heim et al.
Acta neurologica Scandinavica, 126(4), 219-228 (2012-05-29)
Vigabatrin (VGB), an irreversible inhibitor of gamma-aminobutyric acid (GABA) transaminase, is approved as adjunct treatment of refractory partial seizures as well as infantile spasms. Although VGB has been proven to be effective, its use is limited by the risk of
G T Plant et al.
Acta neurologica Scandinavica. Supplementum, (192)(192), 57-71 (2011-11-09)
Vigabatrin is an irreversible inhibitor of γ-aminobutyric acid (GABA) transaminase. It is effective as adjunctive therapy for adult patients with refractory complex partial seizures (rCPS) who have inadequately responded to several alternative treatments and as monotherapy for children aged 1
J M Pellock
Acta neurologica Scandinavica. Supplementum, (192)(192), 83-91 (2011-11-09)
Vigabatrin is an effective and well-tolerated antiepileptic drug (AED) for the treatment of refractory complex partial seizures (rCPS) and infantile spasms (IS), but its benefits must be evaluated in conjunction with its risk of retinopathy with the development of peripheral
S D Walker et al.
Acta neurologica Scandinavica. Supplementum, (192)(192), 72-82 (2011-11-09)
Vigabatrin is an effective antiepileptic drug (AED) for the treatment of refractory complex partial seizures (rCPS) and infantile spasms (IS). In clinical trials, vigabatrin was generally well-tolerated with an adverse event profile similar to that of other AEDs. The most
Justin A Tolman et al.
Expert opinion on pharmacotherapy, 10(18), 3077-3089 (2009-12-04)
Vigabatrin (Sabril) was approved in the USA in mid-2009 for the adjunctive treatment of refractory complex partial seizures and as treatment of infantile spasms. Vigabatrin's more than 30-year history of research and development is condensed into a clinically relevant review

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持